Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rosiglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 15/20 | 1.00 |
| ▸ | RXRA | P19793 | 2/20 | 0.87 |
| ▸ | RARG | P13631 | 1/20 | 0.87 |
| ▸ | PPARA | Q07869 | 2/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rosiglitazone SCHEMBL7052472 | 1.00 | PPARG (1.00) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL5169 | 1.00 | PPARG (1.00) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL11957687 | 1.00 | PPARG (1.00) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL2355017 | 1.00 | PPARG (1.00) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL3375739 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL6976956 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL1489117 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL3377103 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL5468691 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL3381790 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561704-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2025-06-04 | — | — | EP | claimed |
| US-20240316048-A1 | Prevention of Pancreatic Cell Degeneration | MELIOR PHARMACEUTICALS I, INC. | 2024-09-26 | — | — | US | claimed |
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | claimed |
| CN-110859839-B | Application of thiazolidinedione compound in preparation of anti-adenovirus medicament | 中国人民解放军军事科学院军事医学研究院 | 2023-04-18 | — | — | CN | claimed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | claimed |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4635565-A1 | PRENYLATED TETRAHYDROQUINOLINES AND QUINOLINES WITH PPAR AGONIST ACTIVITY | Fundación para la Investigación del Hospital Clínico de la Comunidad Valenciana (INCLIVA) (ES) | 2025-10-22 | — | — | EP | disclosed |
| EP-4561704-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025049558-A1 | TREATMENT OF LIVER DISEASE OR METABOLIC DISORDER WITH FOLLICULIN INTERACTING PROTEIN 1 (FNIP1) INHIBITORS AND/OR FOLLICULIN (FLCN) INHIBITORS | REGENERON PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-113166204-B | Cyclic peptides as inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-113166114-B | Cyclic tetramer compounds as inhibitors of proprotein convertase subtilisin/KEXIN type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-119174759-A | Thiazolidinedione compound, pharmaceutical composition and application thereof | 上海科技大学 | 2024-12-24 | — | — | CN | disclosed |
| CN-110859839-B | Application of thiazolidinedione compound in preparation of anti-adenovirus medicament | 中国人民解放军军事科学院军事医学研究院 | 2023-04-18 | — | — | CN | disclosed |
| CN-110859839-B | Application of thiazolidinedione compound in preparation of anti-adenovirus medicament | 中国人民解放军军事科学院军事医学研究院 | 2023-04-18 | — | — | CN | disclosed |
| CN-110785170-B | Treatment of adipocytes | 梅里奥尔医药I公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | disclosed |
| WO-2022233460-A1 | COMPOSITION COMPRISING PPAR-MODULATOR AND AN UROLITHIN DERIVATIVE AND USES THEREOF | Universite de Bordeaux (FR) | 2022-11-10 | — | — | WO | disclosed |
| EP-4062911-A1 | USE OF PPARY AGONISTS FOR THE TREATMENT OF PRIMARY HEREDITARY DISEASES OF THE CARDIAC MUSCLE (CARDIOMYOPATHIES) | Preventage Therapeutics GmbH (DE) | 2022-09-28 | — | — | EP | disclosed |
| CN-111018834-B | Aminopyrimidine butenone derivatives as PPAR-gamma modulators | 成都理工大学 | 2022-07-15 | — | — | CN | disclosed |
| CN-114209681-A | Application of sea cucumber long-chain base and derivatives thereof in preparation of PPAR-gamma regulating product | 中国海洋大学 | 2022-03-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | PPARG 4105/4885RXRA 4621/4885RARG 4840/4885 |
| US-20240316048-A1 | Prevention of Pancreatic Cell Degeneration | IAPP, AMY2A, PNLIP | PPARG 656/4885RXRA 1437/4885RARG 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.